证券代码：301391 证券简称：卡莱特 公告编号：2025-040 卡莱特云科技股份有限公司 第二届监事会第九次会议决议公告 本公司及监事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 卡莱特云科技股份有限公司（以下简称"公司"）第二届监事会第九次会议 通知于 2025 年 8 月 1 日以邮件的形式发出，会议于 2025 年 8 月 13 日以现场结 合通讯表决的方式召开。会议由监事会主席张雄涛先生主持，会议应出席的监事 3 人，实际出席的监事 3 人。本次会议的召集和召开符合《中华人民共和国公司 法》（以下简称"《公司法》"）等相关法律、法规以及《卡莱特云科技股份有 限公司章程》的规定。 二、监事会会议审议情况 1、审议通过《关于<2025 年半年度报告>及其摘要的议案》 经审核，监事会认为：公司董事会对《2025 年半年度报告》及其摘要的编制 和审议程序符合法律、法规和《公司章程》的有关规定，其内容与格式符合中国 证监会和深圳证券交易所的各项规定，所包含的信息真实、准确、完整地反映了 公司 2025 年半年度的财务状况、经营成果和现金流量，不 ...

证券代码：301391 证券简称：卡莱特 公告编号：2025-039 卡莱特云科技股份有限公司 第二届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 卡莱特云科技股份有限公司（以下简称"公司"）第二届董事会第十一次会 议于 2025 年 8 月 13 日以现场结合通讯表决的方式召开。会议通知已于 2025 年 8 月 1 日通过邮件方式送达全体董事。本次会议由董事长周锦志先生主持，会 议应出席的董事 7 人，实际出席的董事 7 人，其中章成、张忠培、刘昱熙以通 讯方式出席会议。公司监事、高级管理人员列席了本次会议。本次会议的召集 和召开符合《中华人民共和国公司法》等相关法律、法规以及《卡莱特云科技 股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议通过了《关于<2025 年半年度报告>及其摘要的议案》 表决结果：赞成票 7 票，反对票 0 票，弃权票 0 票。 具体内容详见公司同日于巨潮资讯网（www.cninfo.com.cn）披露的《2025 年半年度募集资金存放、管理与使用情况的专项报告》（公告 ...

卡莱特云科技股份有限公司 2025 年半年度报告全文 卡莱特云科技股份有限公司 2025 年半年度报告 2025-041 2025 年 8 月 15 日 1 卡莱特云科技股份有限公司 2025 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容 的真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担 个别和连带的法律责任。 公司负责人周锦志、主管会计工作负责人劳雁娥及会计机构负责人(会计 主管人员)劳雁娥声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本报告中涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺， 也不代表公司对未来的盈利预测，能否实现取决于市场状况变化等多种因素， 敬请投资者注意投资风险。 公司需遵守《深圳证券交易所上市公司自律监管指引第 4 号——创业板 行业信息披露》中的"LED 产业链相关业务"的披露要求： 公司在本报告第三节"管理层讨论与分析"之"十、公司面临的风险和应对 措施"，详细描述了公司经营中可能存在的风险及应对措施，敬请投资者关注 相关内容。 公司 ...

Group 1 - The brain-computer interface sector is experiencing a significant rise, with several companies showing strong performance [1] - Innovative Medical has reached its daily limit increase, indicating strong investor interest and confidence [1] - Qi Sheng Technology previously hit its limit up, reflecting positive market sentiment towards the company [1] Group 2 - Companies such as Xiangyu Medical, Mcland, and Beiyikang have all seen their stock prices increase by over 10%, showcasing a broader trend of growth in the sector [1] - Other companies including Aipeng Medical, Chengyitong, Sanbo Brain Science, Weisi Medical, and Lihua Science and Technology are also experiencing upward movement in their stock prices [1]

Core Insights - The report highlights that in 2024, the total salary for A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1][3]. Salary Overview - The average salary for company secretaries in the machinery and automation equipment sector is approximately 830,100 yuan, with the highest salary being 6.2217 million yuan for Sun Feng from Saiteng Co., and the lowest being 152,500 yuan for Chen Zhen from Oke Technology [1]. - The salary distribution shows that the majority, 34 individuals, earn between 500,000 to 1 million yuan, accounting for 50% of the total [1]. Salary Changes - Compared to 2023, the average salary in 2024 increased by 13,100 yuan, representing an 8% rise [3]. - Zhang Yong from Inno Laser saw a significant salary increase to 1.0507 million yuan, up 605,600 yuan from 445,100 yuan in 2023, marking a 136% increase [3]. Age Distribution - The average age of company secretaries is approximately 43.54 years, with the largest age group being 40-49 years, comprising about 50% of the total [3]. - The oldest secretary is Wu Qiunong from Haide Control, aged 59, earning 1.0475 million yuan, while the youngest is Chen Zhen from Oke Technology, aged 29 [3]. Educational Background - The educational distribution includes 1 PhD, 32 Master's degrees, 29 Bachelor's degrees, and 5 with vocational or lower education, with average salaries of 857,300 yuan, 930,700 yuan, 572,400 yuan, and 666,100 yuan respectively [5]. - Lei Sai Intelligent's Xiang Shaohua, holding a PhD, earns 857,300 yuan, while Xu Xuhua from Changfu Co. with a vocational degree earns 591,800 yuan [5]. Compliance Issues - There are 6 company secretaries who received warnings, public notifications, or internal communications regarding compliance issues for the period of 2024-2025 [7].

Core Viewpoint - The article highlights the significant policy support for the brain-computer interface (BCI) industry, with a focus on the implementation opinions released by multiple government departments aimed at fostering innovation and development in this sector by 2027 [1][2]. Summary by Sections Policy Implementation - On August 7, a joint implementation opinion was released by several government bodies, outlining 17 specific measures to promote the innovation and development of the BCI industry [2]. - The opinion sets a target for breakthroughs in key BCI technologies by 2027, establishing advanced technical, industrial, and standard systems [4]. Technological Development Goals - By 2027, the performance of electrodes, chips, and complete products is expected to reach international advanced levels, with applications in industrial manufacturing, healthcare, and consumer life accelerating [4]. - By 2030, the BCI industry is anticipated to significantly enhance its innovation capabilities, nurturing 2 to 3 globally influential leading enterprises and a number of specialized small and medium-sized enterprises [4]. Product Innovation - The implementation opinion emphasizes the need for high-performance products, including breakthroughs in implantable devices and the development of new product forms such as adhesive, ear, and clip-on devices [4][5]. - There is a focus on developing high-channel, high-speed brain signal acquisition chips and auxiliary devices that integrate multiple physiological signals to improve interaction control and perception assessment accuracy [5]. Industry Growth and Support - The opinion encourages the growth of leading enterprises in the BCI field and the formation of industry innovation consortia, supporting the cultivation of technology-driven small and medium enterprises [5]. - The BCI industry is expected to receive substantial support from the government, with new pricing mechanisms for medical devices related to BCI technology being established [7]. Market Potential - The global BCI market is projected to reach approximately $7 billion by 2030, with a compound annual growth rate (CAGR) of 16.4% from 2025 to 2030 [8]. - The domestic BCI market is expected to grow significantly, with a market size of 1.73 billion yuan in 2023, reflecting an increase of over 5% compared to 2020 [8]. - By 2040, the Chinese BCI market is forecasted to exceed 120 billion yuan, with an annual growth rate of 26% [8].

证券代码：301391 证券简称：卡莱特 公告编号：2025-038 卡莱特云科技股份有限公司 关于签订募集资金四方监管协议的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、募集资金的情况概述 经中国证券监督管理委员会（以下简称"中国证监会"）《关于同意卡莱特 云科技股份有限公司首次公开发行股票注册的批复》（证监许可[2022]1920 号） 同意注册，卡莱特云科技股份有限公司（以下简称"公司"）向社会公开发行人 民币普通股（A股）1,700 万股，发行价格为 96 元/股，本次发行募集资金总额为 1,632,000,000.00 元，扣除发行费用 176,733,152.98 元（不含增值税）后，募集资 金净额为 1,455,266,847.02 元。上述募集资金到位后，安永华明会计师事务所（特 殊普通合伙）进行了验证，并于 2022 年 11 月 28 日出具了安永华明（2022）验 字第 61647772_H01 号《验资报告》。 二、本次募集资金专户的开立情况和《募集资金四方监管协议》的签订情况 （一）协议签署主体 1、有关各方 甲方一：卡莱特 ...

Core Viewpoint - The company is focusing on expanding its production capacity and product line through innovation and strategic investments, particularly in the rehabilitation medical device sector [1][2][4]. Group 1: Investment and Expansion - The company is investing 400 million yuan in a new smart manufacturing base in Chengdu, expected to be completed by August this year, aimed at increasing production capacity and improving efficiency [1]. - The company has obtained 19 medical device registration certificates, covering various fields such as electrotherapy, oxygen therapy, and biofeedback [2]. Group 2: Product Development and Innovation - The company has launched several new products this year, including mid-frequency therapy devices and pelvic floor rehabilitation devices, which are essential for expanding market reach [1][2]. - The interference electric therapy device, a key product, has been developed with proprietary technology and patents, enhancing the company's competitiveness in the electrotherapy market [1]. - The company is also focusing on consumer health products, leveraging its expertise in professional medical devices to create innovative solutions for home use [3]. Group 3: Market Strategy - The company is actively expanding its overseas market presence, with products already reaching 70 countries, and plans to enhance its export efforts [4]. - The company recognizes the growing demand from the elderly population and is developing products tailored to their rehabilitation and health needs, such as portable oxygen machines and mid-frequency therapy devices [4].

Core Viewpoint - The company, Kaleite Cloud Technology Co., Ltd., has announced its profit distribution plan for the fiscal year 2024, which includes a cash dividend of RMB 11,052,909.60, distributed at a rate of RMB 1.2 per 10 shares, excluding repurchased shares [1][2]. Summary by Sections Profit Distribution Plan - The total cash dividend to be distributed is RMB 11,052,909.60, based on a total share count of 92,107,580 shares, with a distribution rate of RMB 0.12 per share [1][2]. - The cash dividend will not include stock dividends or capital reserve transfers [1][2]. Shareholder Meeting Approval - The profit distribution plan was approved at the shareholder meeting held on May 23, 2025 [1][2]. Shareholder Registration and Ex-Dividend Dates - The record date for the distribution is June 12, 2025, and the ex-dividend date is June 13, 2025 [2][4]. Dividend Taxation - The company will not withhold personal income tax for certain shareholders, with tax rates varying based on the type of shares held [2][4].

卡莱特云科技股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 证券代码：301391 证券简称：卡莱特 公告编号：2025-037 1、根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指 引第 9 号——回购股份》等相关规定，卡莱特云科技股份有限公司（以下简称"公 司"）通过回购专用证券账户（以下简称"回购专户"）持有的公司股份不享有 参与本次利润分配的权利。 公司 2024 年度利润分配方案为：以公司现有总股本剔除已回购股份 2,907,231 股后的股份总数 92,107,580 股为基数，向全体股东每 10 股派 1.2 元人 民币现金（含税），合计派发现金股利人民币 11,052,909.60 元（含税），不送红 股、不以资本公积金转增股本。实施上述分配后，公司剩余可供分配利润结转到 以后年度。公司本次实际现金分红的总金额=实际参与分配的总股本×分配比例， 即 11,052,909.60 元=92,107,580 股×0.12 元/股。 2、本次权益分派实施后，按公司总股本折算每 10 ...